Zura Bio Limited (NASDAQ:ZURA) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Analysts have given Zura Bio a consensus rating of Moderate Buy from six brokerages, with an average 12‑month price target of $10.75 and individual targets as high as $15 amid a mix of ratings from sell to strong buy.
• Major shareholder Ai Biotechnology LLC bought 2,000,000 shares at $6.25 on Feb. 26 (a 43.9% increase to 6,552,725 shares); insiders now own 14.23% of the company.
• Zura traded around $5.68 with a market cap of $538.92 million and a 12‑month range of $0.98–$7.44, and it reported quarterly EPS of -$0.49 (missing estimates) with analysts forecasting about -0.65 EPS for the year.

Zura Bio Limited (NASDAQ:ZURA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $10.75.

Several research analysts recently commented on the company. Chardan Capital boosted their price target on Zura Bio from $10.00 to $11.00 and gave the stock a "buy" rating in a research note on Monday, March 23rd. Wedbush assumed coverage on Zura Bio in a research note on Monday, February 9th. They issued an "outperform" rating and a $15.00 price target on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Zura Bio in a research note on Wednesday, April 8th. Finally, Oppenheimer cut their price target on Zura Bio from $16.00 to $15.00 and set an "outperform" rating on the stock in a research note on Friday, March 20th.

Insider Activity at Zura Bio

In other Zura Bio news, major shareholder Ai Biotechnology Llc purchased 2,000,000 shares of the business's stock in a transaction that occurred on Thursday, February 26th. The shares were acquired at an average price of $6.25 per share, for a total transaction of $12,500,000.00. Following the completion of the purchase, the insider owned 6,552,725 shares in the company, valued at $40,954,531.25. The trade was a 43.93% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 14.23% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ZURA. Bank of America Corp DE lifted its stake in shares of Zura Bio by 31.9% in the fourth quarter. Bank of America Corp DE now owns 41,222 shares of the company's stock worth $103,000 after acquiring an additional 9,966 shares in the last quarter. AQR Capital Management LLC acquired a new stake in Zura Bio during the first quarter valued at approximately $72,000. JPMorgan Chase & Co. raised its stake in Zura Bio by 78.7% during the second quarter. JPMorgan Chase & Co. now owns 4,659,951 shares of the company's stock valued at $4,893,000 after buying an additional 2,052,732 shares in the last quarter. Jane Street Group LLC acquired a new stake in Zura Bio during the second quarter valued at approximately $113,000. Finally, Forefront Wealth Partners LLC acquired a new stake in Zura Bio during the third quarter valued at approximately $93,000. Institutional investors and hedge funds own 61.14% of the company's stock.

Zura Bio Price Performance

Shares of ZURA opened at $5.68 on Tuesday. The stock's 50-day moving average is $6.21 and its two-hundred day moving average is $4.98. The stock has a market cap of $538.92 million, a PE ratio of -5.36 and a beta of 0.24. Zura Bio has a 12 month low of $0.98 and a 12 month high of $7.44.

Zura Bio (NASDAQ:ZURA - Get Free Report) last issued its quarterly earnings data on Thursday, March 19th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.31). On average, research analysts anticipate that Zura Bio will post -0.65 earnings per share for the current year.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.